Dose reduction or complete cyclosporine withdrawal convoyed by MMF or rapamycin administration in kidney allograft recipients
Abstract
In 31 kidney allograft recipients cyclosporine (CsA) dosage was gradually reduced below a ‘therapeutic window’ convoyed by MMF or Rapamycin administration. A graft biopsy performed before the start of the CsA withdrawal revealed a normal picture in 7 patients and different pathological disturbances in the rests. CsA was withdrawn in 23 patients who were followed up for further 284 ± 153 days. One graft was lost after the CsA withdrawal due to CAN progression. In other patients an increase in glomerular filtration rate (p < 0,05) and a decrease in blood urea, creatinine level, and blood pressure were found. The decrease in blood urea and arterial blood pressure were statistically significant.
About the Authors
M. M. Kaabak
Российский научный центр хирургии Российской академии медицинских наук, г. Москва
Russian Federation
Russian Federation
N. N. Babenko
Российский научный центр хирургии Российской академии медицинских наук, г. Москва
Russian Federation
Russian Federation
J. I. Kurakina
Российский научный центр хирургии Российской академии медицинских наук, г. Москва
Russian Federation
Russian Federation
References
1. Каабак М.М., Самсонов Д.В., Бабенко Н.Н., Шереметьева Г.Ф., Морозова М.М., Куракина Ж.И., Чепрасова Т.Ю. Рациональное использование рапамицина (сиролимуса) в современной многокомпонентной иммуносупрессии при трансплантации почки. Нефрология и диализ 2003; 5; 4: 379-387.
2. Каабак М.М., Куракина Ж.И. Частичная или полная отмена циклоспорина у пациентов после трансплантации почки на фоне назначения ММФ. Нефрология и диализ 2002; 4; 3: 191-195.
3. Щербакова Е.О., Прокопенко Е.И., Ватазин А.В., Полякова Г.А., Пасов С.А., Будникова Н.Е., Гулимова С.Ю. Пиелонефрит нефункционирующего почечного аллотрансплантата, потребовавший выполнения трансплантатэктомии через 23 года после пересадки почки. Нефрология и диализ 2003; 5; 4: 401-404.
4. Aleksic I., Baryalei M., Pieske B., Scorn B., Strauch J., Sorbu H., Dalichau H. Тhe amelioration of a deteriorated function of allografted kidneys in patients receiving Mycophenolate Mofetil and small doses of Sandimmune. Transplantation 2000; 70: 1586-1590.
5. Cooper P., Mason J., Donatsch P. et al. Calcium antagonist therapy prevents chronic cyclosporine nephrotoxicity after renal transplantation: a prospective study. Kidney Int 1990; 37: 595.
6. Dudley Christopher R.K. The MMF «creeping creatinine» study group. MMF substitution for CsA is effective and safe treatment of chronic allograft disfunction; results of a multi-center randomized controlled study. Am J Transplant April, 2002; 2; I S3: 148, abs 41.
7. English J., Pilepich M.V., Sicard G.A. The effect of cyclosporine on warm ischemic kidneys in rats. Transplantation 1987; 44: 135-141.
8. Houde I., Isenring P., Boucher D., Noel R., Lachanche J.-G. Mycophenolate Mofetil - alternative to cyclosporine А for long term immunosuppression in kidney transplantation. Transplantation 2000; 70: 1251-1253.
9. Kahan B.D. Immunosuppressive therapy with cyclosporine for renal transplantation. Circulation 1987; 75 (1): 40.
10. Kaskel F.J., Devarajan P., Arbeit L.A., Moore L.C. Effects of cyclosporine on renal hemodynamics and autoregulation in rats. Transplant 1988; Proc 20 (3 Suppl. 3): 603-696.
11. Keown P.A., Stiller C.R., Wallace A.C. In: Williams G.M., Burdick J.F., Solez K. (eds): Daily renal hipoperfusion induced by cyclosporine in patients with renal transplantation. New York Marcel Dekker: Kidney Transplant Rejection 1986.
12. Kremer S.G., Margolis B., Goldberg H. et al. Cyclosporine A - a phase I clinical trial and pilot rescue study. Kidney Int 1988; 33: 361.
13. Mayson J., Thiel G., Spichtin H.P. et al. The year in review. Transplantation 1994; 15: 2821.
14. Moran M., Mozes M.F., Maddux M.S. et al. Рharmakocinetic strategies for cyclosporine therapy in organ transplantation. N Engl J Med 1990; 322 (17): 1183.
15. Morris P.J., Chapman J.R., Allen R.D. et al. Immunologiсal and non immunological factors with Neoral in renal transplant recipients: an interim report. Lancet 1989; 1: 586.
16. Muller-Schweinitzer E., Mason J., Olea Baza I. Mechanisms of cyclosporine-induced hypertension. Kidney Int 1990; 37: 598.
17. Mycophenolate Mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: 391.
18. Myers B.D., Newton L., Boshkos C. et al. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Transplantation 1988; 46: 694.
19. Myers B.D., Sibley R., Newton L. et al. Cyclosporine A treatment and evaluation of glomerular filtration rate in patients with a transplanted kidney. Kidney Int 1988; 33: 590.
20. Myers B.D. The use of cyclosporine in renal recipients. Kidney Int 1986; 30: 964.
21. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., Leichtman A.B., Cibrik D., Magee J.C., Wolfe R.A., Agodoa L.Y., Kaplan B. MMF reduces late renal allograft loss independently of acute rejection. Transplantation 2000; 69: 2405-2409.
22. Schnuelle P. et al. Open randomized trial comparing early withdrawal of either Cyclosporine or Mycophenolate Mofetil in stable renal transplantation recipients initially treated with a triple Drug regimen. J Am Soc Nephrol 2002; 13: 536-543.
23. Schrama Y., Joles J., van Tol A., Boer P., Koomas H., Hen R. Conversion to MMF according with gradual cyсlosporine withdrawal in stable kidney graft recipients. Transplantation 2000; 69: 376-383.
24. Xue H., Bukoski R.D., McCarron D.A. еt al. Diagnosis of renal transplant rejection in the cyclosporine era. Transplantation 1987; 43: 715.
Review
For citations:
Kaabak M.M., Babenko N.N., Kurakina J.I. Dose reduction or complete cyclosporine withdrawal convoyed by MMF or rapamycin administration in kidney allograft recipients. Nephrology and Dialysis. 2005;7(1):77-86. (In Russ.)
Views:
10
Email this article 